[P26-8] P26-8: Oncologic drugs (4): Pharmacokinetics, TDM practice

[P26-8-5] Pharmacokinetic analysis of irinotecan and its metabolite to evaluate UGT1A1 and CYP3A activities in patients with UGT1A1 gene polymorphism

Akitomo Yokokawa¹, Shun Kaneko², Sayuri Endo³, Ryohei Hirano⁴, Fumio Nagashima⁵, Daisuke Naruge⁶, Naohiro Okano⁷, Takaaki Kobayashi⁸, Kirio Kawai⁹, Junji Furuse¹⁰, Hiromi Shibasaki-Hirano¹¹, Takashi Furuta¹² (1.Tokyo University of Pharmacy and Life Sciences, 2.Tokyo University of Pharmacy and Life Sciences, 3.Tokyo University of Pharmacy and Life Sciences, 4.Tokyo University of Pharmacy and Life Sciences, 5.Kyorin University, Faculty of Medicine, 6.Kyorin University, Faculty of Medicine, 7.Kyorin University, Faculty of Medicine, 8.Kyorin University, Faculty of Medicine, 9.Kyorin University, Faculty of Medicine, 10.Kyorin University, Faculty of Medicine, 11.Tokyo University of Pharmacy and Life Sciences, 12.Tokyo University of Pharmacy and Life Sciences)

Keywords:irinotecan, pharmacokinetics, compartment model